Literature DB >> 28508175

Comparison of R-CVP with R-CHOP for very elderly patients aged 80 or over with diffuse large B cell lymphoma.

Hideki Arakaki1, Tomonori Nakazato2, Yuki Osada1, Chisako Ito1, Yoshinobu Aisa1, Takehiko Mori3.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28508175     DOI： 10.1007/s00277-017-3017-7

Source DB:  PubMed          Journal:  Ann Hematol        ISSN： 0939-5555            Impact factor:   3.673


× No keyword cloud information.
  2 in total

1.  A phase II multicenter study of the anti-CD19 antibody drug conjugate coltuximab ravtansine (SAR3419) in patients with relapsed or refractory diffuse large B-cell lymphoma previously treated with rituximab-based immunotherapy.

Authors:  Marek Trnĕný; Gregor Verhoef; Martin Js Dyer; Dina Ben Yehuda; Caterina Patti; Miguel Canales; Andrés Lopez; Farrukh T Awan; Paul G Montgomery; Andrea Janikova; Anna M Barbui; Kazimierz Sulek; Maria J Terol; John Radford; Anna Guidetti; Massimo Di Nicola; Laure Siraudin; Laurence Hatteville; Sandrine Schwab; Corina Oprea; Alessandro M Gianni
Journal:  Haematologica       Date:  2018-05-10       Impact factor: 9.941

2.  Frontline treatments in extremely elderly patients with diffuse large B-cell lymphoma: a population-based study in Taiwan, 2010-2015.

Authors:  Huai-Hsuan Huang; Bor-Sheng Ko; Ho-Min Chen; Li-Ju Chen; Chen-Yu Wang; Fei-Yuan Hsiao
Journal:  Immun Ageing       Date:  2020-06-10       Impact factor: 6.400
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.